SAB Biotherapeutics Inc (SABS)

SAB Biotherapeutics Inc (SABS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $262M; returns 1 day -6.6%, 1 week +12.3%, 1 year -2.7%.

SAB Biotherapeutics (rebranded as SAB BIO) is a clinical-stage biopharmaceutical company utilizing a proprietary 'DiversitAb' platform to produce fully human polyclonal antibodies (hIgG) using genetically engineered (transchromosomic) bovine herds.

Groups SABS belongs to

• Biotechnology
• Biopharmaceutical
• Type 1 Diabetes
• Clinical Stage
• Clinical Stage Biotech
• Autoimmune Diseases
• Clinical Stage Biopharma
• Immunotherapy
• Antibody Therapeutics
• Healthcare
• Life Sciences

SABS financial model: income statement, cash flow and balance sheet